NCT03194776 - Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

September 7, 2018

Study Completion Date

December 27, 2018

Conditions

Peripheral Artery Disease (PAD); Intermittent Claudication

Interventions

DRUG

LLG783

LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.

DRUG

Placebo

Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.

Trial Locations (8)

Novartis Investigative Site, Taipei

Novartis Investigative Site, Berlin

Novartis Investigative Site, Berlin

Novartis Investigative Site, Taipei

Novartis Investigative Site, Kiel

Novartis Investigative Site, Jacksonville

Novartis Investigative Site, Magdeburg

Novartis Investigative Site, Columbus